Estimated Health Benefits, Costs, and Cost-Effectiveness of Eliminating Industrial Trans-Fatty Acids in Nigeria

No Thumbnail Available
File version
Author(s)
Marklund, Matti
Aminde, Leopold
Wanjau, Mary
Ale, Boni
Ojo, Adedayo
Okoro, Clementina
Adegboye, Abimbola
Veerman, Lennert
Wu, Jason
Huffman, Mark
Ojji, Dike
Primary Supervisor
Other Supervisors
Editor(s)
Date
2023
Size
File type(s)
Location

Boston, United States

License
Abstract

Objectives: To estimate the potential health gains, costs, and cost-effectiveness of a mandatory limit on industrial trans fatty acids (iTFA) in the Nigerian food supply.

Methods: We used Markov cohort models to estimate the effect on ischemic heart disease (IHD) burden, costs, and cost-effectiveness of a mandatory iTFA-limit (≤2% of all fats) for foods in Nigeria. Data on demographics, IHD epidemiology, and trans-fatty acid intake were derived from the 2019 Global Burden of Disease Study. We calculated the IHD burden attributable to iTFA by comparing the current trans-fatty acid intake to counterfactual settings with complete elimination of iTFA intake. Policy implementation costs (including government costs for legislation and monitoring, and industry costs for product reformulation), avoided IHD events and deaths, health-adjusted life years (HALYs) gained, and healthcare costs saved were estimated over 10 years and lifetime of the Nigerian population. Incremental cost-effectiveness ratios using net costs (i.e., implementation costs minus healthcare cost savings) and HALYs gained (both discounted at 3%) were used to assess cost-effectiveness.

Results: Over the first 10 years, elimination of iTFA intake was estimated to prevent 9,996 (95% uncertainty interval: 8,870; 11,118): IHD deaths and 66,569 (58,862; 74,083) IHD events, and to save 90 million USD (78; 102) in total healthcare costs. The corresponding estimates over the lifetime were 259,934 (228,736; 290,191), 479,308 (95% UI: 420,472; 538,177), and ~518 (450; 587). Policy implementation costs (government plus industry) were estimated as 18 million USD (12; 25) over the first 10 years, and 27 million USD (20; 35) over the population lifetime. The intervention was estimated to be cost-saving. Findings were robust across several deterministic sensitivity analyses (Figure).

Conclusions: Our findings support legislating a mandatory limit of iTFAs as a cost-saving strategy to avert substantial numbers of IHD events and deaths in Nigeria.

Journal Title

Circulation

Conference Title

Abstracts From the American Heart Association's Epidemiology and Prevention/Lifestyle and Cardiometabolic Health 2023 Scientific Sessions

Book Title
Edition
Volume

147

Issue

Suppl_1

Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject

Health economics

Epidemiological modelling

Nutrition and dietetics

Cardiovascular medicine and haematology

Clinical sciences

Sports science and exercise

Persistent link to this record
Citation

Marklund, M; Aminde, L; Wanjau, M; Ale, B; Ojo, A; Okoro, C; Adegboye, A; Veerman, L; Wu, J; Huffman, M; Ojji, D, Estimated Health Benefits, Costs, and Cost-Effectiveness of Eliminating Industrial Trans-Fatty Acids in Nigeria, Circulation, 2023, 147 (Suppl_1), pp. AP223